Advances in Diabetes and Heart Disease From ESC 2022

Pardeep Jhund, MD


September 14, 2022

Professor Pardeep Jhund, from the University of Glasgow, United Kingdom, discusses highlights in diabetes and heart disease presented at the European Society of Cardiology Congress 2022.

He begins with a Danish study of the causes of excess mortality in individuals who have diabetes but do not have coronary artery disease. This showed that, even in these patients, greater efforts are required to improve outcomes.

A second Danish epidemiologic study examines the prevalence of diabetic neuropathy and cardiovascular outcomes. Worryingly, it found that around half of patients did not have their urinary albumin measured.

Next, Prof Jhund examines a follow-up analysis of the DANISH trial, which showed that implantable cardioverter-defibrillators were effective in reducing mortality, but only in individuals without diabetes.

He moves on to a pooled analysis of DECLARE-TIMI 58 and DAPA-CKD, which revealed that dapagliflozin consistently reduced kidney and cardiovascular events regardless of baseline eGFR and urinary albumin.

Finally, he discusses a large study addressing adherence rates for drugs in type 2 diabetes. The data on more than 38,000 patients showed that initiating therapy with an SGLT2 inhibitor or a GLP-1R agonist was associated with comparably high rates of adherence, which were unaffected by the presence or absence of cardiovascular disease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.